Open Access
- 1 August 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (9)
Abstract
We thank Xia et al. for raising some interesting points. Firstly, we recognize the peculiarity of rectal tumors, and therefore an exploratory analysis differentiating rectal vs descending or sigmoid colon was conducted and is available in the Supplementary Materials. Secondly, an increasing number of prognostic variables in metastatic colorectal cancer (CRC) has been identified in the last years, but many of them were not collected in clinical studies conducted a decade ago. All available data with a possible prognostic implication were included in the multivariable model to estimate the independent role of tumor location. Thirdly, the relative impact of the addition of bevacizumab was estimated through an adjusted interaction test between tumor location and treatment effect.Keywords
This publication has 12 references indexed in Scilit:
- Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trialAnnals of Oncology, 2015
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS StudiesClinical Cancer Research, 2014
- Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)Annals of Oncology, 2014
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon CancerJNCI: Journal of the National Cancer Institute, 2012
- Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare DataJournal of Clinical Oncology, 2011
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal CancerJournal of Clinical Oncology, 2011
- Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classesBMC Cancer, 2010
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 TrialJournal of Clinical Oncology, 2010
- KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS TrialJournal of Clinical Oncology, 2009
- Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?Annals of Surgical Oncology, 2008